Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05121948 |
| Title | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | HiberCell, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | United States | Details | |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | United States | Details | |
| Washington University School of Medicine | Saint Louis | Missouri | 63110 | United States | Details | |
| Sarah Cannon Research Institute /Tennessee Oncology | Nashville | Tennessee | 37203 | United States | Details | |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | United States | Details | |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| Swedish Cancer Institute | Seattle | Washington | 98104 | United States | Details |